Amgen 2007 Annual Report Download - page 86

The increase in U.S. Neulasta®/NEUPOGEN®sales for the year ended December 31, 2006 was driven pri-
marily by demand for Neulasta®, reflecting segment growth. In addition, the increase in demand for Neulasta®
for the year ended December 31, 2006 also includes the impact of a price increase in April 2006. U.S. demand
for Neulasta®continued to benefit from a product label extension based on clinical data demonstrating the value
of first cycle utilization in moderate-high risk chemotherapy regimens. The increase in international Neulasta®/
NEUPOGEN®sales for the year ended December 31, 2006 was driven primarily by demand for Neulasta®.
In addition to the factors mentioned in the “Product sales” section above, future worldwide Neulasta®/
NEUPOGEN®sales growth will be dependent, in part, on such factors as:
• penetration of existing segments;
• competitive products or therapies, including biosimilar products that may be approved in the EU some-
time in 2008 and be available shortly thereafter;
• reimbursement by third-party payers, including governments and private insurance plans;
• adverse events or results from clinical trials or studies performed by us or by others (including our li-
censees or independent investigators), which could expand safety labeling and may negatively impact
healthcare provider prescribing behavior, use of our product, regulatory or private healthcare orga-
nization medical guidelines and reimbursement practices;
• governmental or private organization regulations or guidelines relating to the use of our products;
• cost containment pressures from governments and private insurers on healthcare providers;
• our ability to minimize distraction due to ESA issues;
• pricing strategies;
• patient growth; and
• development of new treatments for cancer and future chemotherapy treatments. For example, those that
are less myelosuppressive may require less Neulasta®/NEUPOGEN®, however, other future chemo-
therapy treatments that are more myelosuppressive, such as dose dense chemotherapy, could require
more Neulasta®/NEUPOGEN®.
See “Item 1A. Risk Factors” for further discussion of certain of the above factors that could impact our fu-
ture product sales.
ENBREL
For the years ended December 31, 2007, 2006 and 2005, total ENBREL sales by geographic region were as
follows (dollar amounts in millions):
2007 Change 2006 Change 2005
ENBREL — U.S. .......................... $3,052 12% $2,736 11% $2,470
ENBREL — International .................... 178 24% 143 39% 103
Total ENBREL ........................ $3,230 12% $2,879 12% $2,573
ENBREL sales growth for the year ended December 31, 2007 was driven by demand due to increases in
both patients and net sales price. While ENBREL continued to maintain a leading position in both rheumatology
and dermatology, the sales growth during the year ended December 31, 2007 was affected by slight share de-
clines in the United States in both segments versus the prior year due to increased competitive activity.
ENBREL sales growth for the year ended December 31, 2006 was driven by increased demand in both the
rheumatology and dermatology segments. The increase in demand for the year ended December 31, 2006 also
includes the impact of a U.S. price increase. While ENBREL continued to maintain a leading position in both
rheumatology and dermatology, we have experienced moderate share loss in both segments in 2006 compared to
2005. ENBREL sales growth was also affected in 2006 by slowing segment growth in dermatology and by in-
creased competitive activities in both segments.
74